Is larotrectinib included in medical insurance when it is launched in China?

As of now, Larotrectinib (Larotrectinib) has not been included in the scope of domestic medical insurance reimbursement. Although the drug has been launched in China, it has not been included in medical insurance since it has not been on the market for a long time, so patients may face certain difficulties in purchasing it in hospitals. Patients are advised to consult their local hospital pharmacy for the latest purchase information when they need to purchase it.

In foreign markets, larotrectinib provides both original drug and generic drug options. The original drugs include the German version, the American version, the European version and the Hong Kong version, with prices ranging from RMB 10,000 to RMB 20,000. In comparison, generic drugs are relatively cheap. There are Laos and Bangladeshi versions to choose from, and the price is generally around two to three thousand. Although the ingredients of original drugs and generic drugs are basically the same, there may be differences in prices due to differences in manufacturers and manufacturing processes.

For patients, the choice of drugs is affected by many factors, including affordability, medical insurance, and personal preferences. Although larotrectinib is not currently covered by health insurance, there are several purchasing options. Patients can choose the appropriate drug version to meet their treatment needs based on their own conditions and needs.

It needs to be emphasized that patients should choose carefully when purchasing drugs and make decisions under the guidance of a doctor or pharmacist. At the same time, patients are advised to pay close attention to relevant policy updates so as to promptly understand whether larotrectinib has been included in the scope of medical insurance reimbursement, as well as changes in related purchasing channels and price information.